Aurinia Stock Dips as Traders Eye Lupkynis Data
Aurinia Pharmaceuticals Inc. slid in Friday’s Nasdaq session. The stock lagged a mixed biotech sector. Traders were watching the Lupkynis sales outlook. There wasn’t a new press release from the company. The stock traded 0.9% lower at $15.21, giving it a market cap near $2.1 billion. The SPDR S&P Biotech ETF edged up around 0.1%. The iShares Nasdaq Biotechnology ETF was off roughly 0.1%.